New hope for advanced cancers: YL201 drug trial launches
Disease control
Ongoing
This study tests a new drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to find the best dose and see if it shrinks tumors or slows disease. Participants must have tried other treatments and have measurable tumors.
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated May 08, 2026 12:03 UTC